More AVP-825 patients reported meaningful pain relief ( patient interpretation ) of migraine within 2 hours of treatment vs placebo device ( 70 % vs 45 % , P < .001 ) , and fewer required rescue medication ( 37 % vs 52 % , P = .02 ) .